We are monitoring the impact of COVID-19 on Europe Narcolepsy Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 6662
Share on
Share on

Europe Narcolepsy Drugs Market Research Report – Segmented By Type, Indication and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 6662
Pages: 145

Europe Narcolepsy Drugs Market Size (2020 to 2025)

The size of the Narcolepsy Drugs Market in Europe is predicted to showcase a robust CAGR from 2020 to 2025. Narcolepsy is a neurological disorder that decreases the ability to regulate sleep cycles.

High discretionary income and growing consciousness regarding the advantages of narcolepsy drugs in the European countries are majorly accelerating the market in this region. More than 25,000 people in the UK are affected by narcolepsy, and nearly 75% of them are not treated as they are not diagnosed or incorrectly diagnosed. The rise in the cases is alarming. In Europe, the H1N1 influenza pandemic has ended in an increase in sleep-related disorders in 2009. The expected growth of sleep disorders because of unhealthy lifestyles and increment in stress levels are some factors accelerating the growth in the region.

The cost associated with the treatment and manufacturing of the drugs required for the medication impedes the market over the period. Strict rules and regulations for the approval of the drugs by the US FDA are hampering the market, and the lengthy approval process also hinders the growth. The deficit of awareness related to the diagnosis and treatment available is restraining the market.

This research report on the Europe Narcolepsy Drugs Market has been segmented & sub-segmented into the following categories:

By Type:

  • Central Nervous System Stimulants
  • Tricyclic Antidepressants
  • Sodium Oxybyzate
  • Selective Serotonin Reuptake Inhibitor
  • Others

By Indication:

  • Daytime Extreme Sleepiness
  • Cataplexia
  • Others

By Country:

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Rest of Europe

Regional Analysis:

Europe is anticipated to hold the second-largest market in narcolepsy over the period. Factors like the usability of funds for research and development of novel drugs and enormous patient count drive the market in the region. Developed economies like France, Italy, and Germany are responsible for market growth due to the surge in the number of obese people. The increasing number of people being affected by narcolepsy and the growth in the disease's severity is fueling the market growth in the region. 

The UK is dominating the European narcolepsy drugs market, accounting for holding a significant share because of the existence of many key players in addition to the appearance of the stellar healthcare system. Germany is witnessed to be the quickest growing in the region over the period. Factors responsible for the area's growth are escalating acquisition rate, increasing spending on the healthcare domain made by the government specifically in the developing economies, firmly established healthcare infrastructure, and growing research and development of new drugs. In Germany, Jazz pharmaceuticals Xyrem are the only drug approved by the US FDA for cataplexy. The pharmaceuticals have received European marketing authorization for Sunosi as one of the treatments for extreme daytime sleepiness in adults with narcolepsy and obstructive sleep apnoea.

Top companies dominating the European Narcolepsy Drugs Market profiled in this report are Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc, Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc, Bioprojet, and Graymark Healthcare, Inc.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Type                              

                                5.1.1 Introduction           

                                5.1.2 Central Nervous System Stimulants             

                                5.1.3 Tricyclic Antidepressants   

                                5.1.4 Sodium Oxybate   

                                5.1.5 Selective Serotonin Reuptake Inhibitor      

                                5.1.6 Others      

                                5.1.7  Y-o-Y Growth Analysis, By Type    

                                5.1.8  Market Attractiveness Analysis, By Type  

                                5.1.9  Market Share Analysis, By Type    

                5.2 Indication                    

                                5.2.1 Introduction           

                                5.2.2 Daytime Extreme Sleepiness          

                                5.2.3 Cataplexia               

                                5.2.4 Others      

                                5.2.5 Y-o-Y Growth Analysis, By Indication           

                                5.2.6 Market Attractiveness Analysis, By Indication         

                                5.2.7 Market Share Analysis, By Indication           

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Type

                                                6.1.3.3 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Type

                                                6.1.4.3 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Type

                                                6.1.5.3 By Indication

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Ligand Pharmaceuticals                         

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Addrenex Pharmaceuticals                  

                8.3 Shire Plc                       

                8.4 Teva Pharmaceutical Industries Ltd.                

                8.5 Arena Pharmaceuticals                          

                8.6 Jazz Pharmaceuticals Plc                       

                8.7 Bioprojet                     

                8.8 Graymark Healthcare, Inc                     

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms by indication along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Narcolepsy Drugs Market, By Type, From 2020 to 2025 (USD Million)
  2. Europe Central Nervous System Stimulants Market, By Region, From 2020 to 2025 (USD Million)
  3. Europe Tricyclic Antidepressants Market, By Region, From 2020 to 2025 (USD Million)
  4. Europe Sodium Oxybate Market, By Region, From 2020 to 2025 (USD Million)
  5. Europe Selective Serotonin Reuptake Inhibitor Market, By Region, From 2020 to 2025 (USD Million)
  6. Europe Others Market, By Region, From 2020 to 2025 (USD Million)
  7. Europe Narcolepsy Drugs Market, By Indication, From 2020 to 2025 (USD Million)
  8. Europe Daytime Extreme Sleepiness Market, By Region, From 2020 to 2025 (USD Million)
  9. Europe Cataplexia Market, By Region, From 2020 to 2025 (USD Million)
  10. Europe Others Market, By Region, From 2020 to 2025 (USD Million)
  11. U.K. Narcolepsy Drugs Market, By Type, From 2020 to 2025 (USD Million)
  12. U.K. Narcolepsy Drugs Market, By Indication, From 2020 to 2025 (USD Million)
  13. Germany Narcolepsy Drugs Market, By Type, From 2020 to 2025 (USD Million)
  14. Germany Narcolepsy Drugs Market, By Indication, From 2020 to 2025 (USD Million)
  15. France Narcolepsy Drugs Market, By Type, From 2020 to 2025 (USD Million)
  16. France Narcolepsy Drugs Market, By Indication, From 2020 to 2025 (USD Million)
  17. Italy Narcolepsy Drugs Market, By Type, From 2020 to 2025 (USD Million)
  18. Italy Narcolepsy Drugs Market, By Indication, From 2020 to 2025 (USD Million)
  19. Spain Narcolepsy Drugs Market, By Type, From 2020 to 2025 (USD Million)
  20. Spain Narcolepsy Drugs Market, By Indication, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample